Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Abscint from Liège, company number BE0749828410, closed financial year 2025 with a result of € 363,834 after tax. For that financial year Abscint recorded a gross margin of € 870,849 and equity of € 5.6 million. Compared with financial year 2024, the result moved from € -1.3 million to € 363,834. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 5.6 million
▲ 60% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 363,834
▲ still € 1.3 million loss in 2024
Profit after tax over the fiscal year.
€ 2.8 million
▲ 29% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -2.7 million.
People and assets in 2025
2.7
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 327,470
▼ 13% vs 2024
€ 121,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 308
▼ 81% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 778,699
▲ € 638,244 vs 2024
€ 350,000 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 483,292
▲ 83% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 28,693
▼ 33% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -249,727 | € -328,168 | € -660,224 | € 870,849 | ▲ € 1.5 million |
| Profit after taxes | € -463,591 | € -1,012,790 | € -1,340,445 | € 363,834 | ▲ € 1.7 million |
| Equity | € 1,295,952 | € 4,480,700 | € 3,467,984 | € 5,557,750 | ▲ 60% |
| Total debts | € 154,155 | € 257,515 | € 804,417 | € 1,291,511 | ▲ 61% |
| Cash | € 985,908 | € 2,990,375 | € 2,149,043 | € 2,780,888 | ▲ 29% |
| Retained profit | € -701,483 | € -1,714,273 | € -3,054,719 | € -2,690,885 | ▲ € 363,834 |
| Bank debt | € 0 | € 0 | € 140,455 | € 778,699 | ▲ € 638,244 |
| Balance sheet total | € 1,450,107 | € 4,738,215 | € 4,272,401 | € 6,849,261 | ▲ 60% |
| Employees (FTE) | - | - | 3 | 2.7 | ▼ 0.3 |
Key figures of Abscint, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Abscint?
What happened at Abscint in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- CBD Consulting SRL stepped down as director. NBB
- Didier Allaer stepped down as director. NBB
- Jacobus Boonen stepped down as director. NBB
- Koen DEWAELE stepped down as director. NBB
- Qbic Venture Partners II SA stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 363,834. Source: NBB ↗
- Koen DEWAELE became a director. NBB
In short
From € 463,591 loss in 2022 to € 363,834 profit in 2025.
Best year ever: 2025, with € 363,834 profit.
On average € 322,500 of value added per employee in 2025.
A new publication or filing at Abscint? We notify you, reason included.
Follow AbscintDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of CBD Consulting, QBIC II FUND ARKIV, NOSHAQ SPIN-OFFS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
AbscintThe shares are held by CBD Consulting (20.5%), QBIC II FUND ARKIV (14.2%) and NOSHAQ SPIN-OFFS (13.9%).
Directors
According to the 2025 annual accounts
Director · represented by Marleen LIMBOURG
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2022 · until 2028
Managing director · represented by Karine CLAUWAERT
Also active at: SILLAR CLINICAL
since 2022 · until 2028
since 2022 · until 2028
since 2022 · until 2028
Koen DEWAELE
Director
since 2023 · until 2028
Director · represented by Sofie BAETEN
Also active at: EYED PHARMA, Accelleran, Indigo Diabetes, QBIC II FUND ARKIV, Blue Foot Membranes, Aloxy, Sentea, UniD Manufacturing +4 more
since 2022 · until 2028
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 23
4000 Liège
Researchdreef 12
1070 Anderlecht
Active since 1 March 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS same network
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0749.828.410
- VAT number
- BE 0749.828.410
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 23, 4000 Liège
- Names & denominations
- Abscint
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 2020
- Peppol
- Active · Active since 19 Jan 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria